Application of ¹⁸F-FDG PET/CT imaging in diagnosing bladder tumor metastasis lesions

Abstract

Bladder tumor is the most common malignant tumor in urinary system and always companied with lymph node metastasis. The accurate staging plays a significant role in treatment for bladder tumor and prognostic evaluation, and the distant metastasis predicts worse prognosis. The objective of this study was to assess the clinical significance of ¹⁸F-FDG PET/CT imaging in diagnosing bladder tumor metastasis lesions. A retrospective analysis of 60 patients with bladder tumor from October 2008 to May 2010 was done. The patients were stratified based on the imaging technique. Among all 60 cases, besides the primary lesion, 81 suspected lesions were spotted and 73 confirmed as metastasis, including 50 lymph node metastases, 22 distant metastases, and 1 bone metastasis. For PET/CT imaging, its sensitivity was 94.5%, specificity 87.5%, positive predictive value 98.6%, negative predictive value 63.6% and accuracy 93.8% respectively. For CT, its sensitivity was 82.2%, specificity 50%, positive predictive value 93.8%, negative predictive value 23.5% and accuracy 79% respectively. PET/CT imaging was superior to CT in sensitivity, specificity and accuracy. In conclusion, ¹⁸F-FDG PET/CT imaging is more significant in diagnosing bladder tumor metastasis lesions.

References

[1] MüllerJ, SchraderM, SchraderAJ, et al.. Value of positron emission tomography in urological neoplasms: More form than substance?. Urologe A, 2012, 51(3): 331-440

[2] ShenYY, KaoCH, YehLH, et al.. Feasible method to successfully uncover a urothelial carcinoma in the urinary bladder on the FDG PET/CT scan masked by physiological urine radioactivity. Clin Nucl Med, 2010, 35(6): 464-466

[3] LoddeM, LacombeL, FriedeJ, et al.. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int, 2010, 106(5): 658-663

[4] PatilVV, WangZJ, SollittoRA, et al.. ¹⁸F-FDG PET/CT of transitional cell carcinoma. Am J Roentgenol, 2009, 193(6): 497-504

[5] JensenTK, HoltP, GerkeO, et al.. Preoperative lymph-node staging of invasive urothelial bladder cancer with ¹⁸F-fluorodeoxyglucose positron emission tomography/ computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol, 2011, 45(2): 122-128

[6] OsmanMM, AltinyayME, AbdelmalikAG, et al.. FDG PET/CT incidental diagnosis of a synchronous bladder cancer as a fourth malignancy in a patient with head and neck cancer. Clin Nucl Med, 2011, 36(6): 496-497

[7] VargasHA, AkinO, SchöderH, et al.. Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol, 2012, 81(12): 4131-4137

[8] HalacM, AliyevA, YılmazS, et al.. Delayed imaging of the pelvis with diluted and filled bladder: a simple and efficient method in FDG PET/CT imaging of bladder carcinoma. Clin Nucl Med, 2012, 37(8): 778-780

[9] YangZ, ChengJ, PanL, et al.. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?. Ann Nucl Med, 2012, 26(7): 571-577

[10] LeeST, LawrentschukN, ScottAM. PET in prostate and bladder tumors. Semin Nucl Med, 2012, 42(4): 231-246

[11] ManoharK, MittalBR, BhattacharyaA, et al.. A rare case of malignant urinary bladder paraganglioma with distant metastases demonstrated by 18F-FDG PET/CT. Clin Nucl Med, 2012, 37(6): e148-149

[12] BertagnaF, MottaF, FisogniS, et al.. Absence of urine production due to renal failure enables clear visualization of primary urinary bladder carcinoma on 18F-FDG PET/CT. Clin Nucl Med, 2012, 37(6): 611-613

[13] OreviM, KleinM, MishaniE, et al.. ¹¹C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline. Clin Nucl Med, 2012, 37(4): e67-72

[14] BelakhlefS, ChurchC, JaniC, et al.. Early dynamic PET/CT and 18F-FDG blood flow imaging in bladder cancer detection: a novel approach. Clin Nucl Med, 2012, 37(4): 366-368

[15] MüllerJ, SchraderM, SchraderAJ, et al.. Value of positron emission tomography in urological neoplasms: more form than substance?. Urologe A, 2012, 51(3): 331-340